公司資料
Allogene Therapeutics 股價、新聞與催化劑
- 股票代碼:
- ALLO
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
2.08 USD (+1.46%)
收盤價
最後更新: 2026年8月17日
708M USD
市值
股價為何變動
As of Aug 17, 2026, ALLO closed up 1.46% at $2.08. No new same-company headline was identified in the current news window.
公司概覽
Allogeneic CAR T Company
Allogene Therapeutics develops off-the-shelf CAR T-cell therapies for cancer and autoimmune disease. Its platform is intended to provide readily available treatment without patient-specific cell collection and manufacturing.
Cema-Cel
Cemacabtagene ansegedleucel, or cema-cel, is a CD19-directed AlloCAR T candidate designed for outpatient administration. It has received FDA Regenerative Medicine Advanced Therapy and Fast Track designations in first-line large B-cell lymphoma consolidation.
MRD-Guided Lymphoma Treatment
The pivotal Phase 2 ALPHA3 study evaluates cema-cel in first-line large B-cell lymphoma patients who remain minimal residual disease-positive after standard treatment. This approach seeks to intervene before overt clinical relapse.
ALLO-329
ALLO-329 is a dual-targeting CD19/CD70 AlloCAR T candidate for autoimmune diseases. Its Dagger technology is designed to reduce host rejection and potentially limit dependence on conventional chemotherapy-based lymphodepletion.
未來催化劑
- Clinical and translational data from the Phase 1 RESOLUTION study of ALLO-329 in the fourth quarter of 2026.
- Interim event-free-survival update from the pivotal Phase 2 ALPHA3 study in mid-2027.
- Completion of ALPHA3 enrollment by the end of 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。